Peptides for Pets: Dogs, Cats, Horses

Veterinary peptide use predates the human biohacker boom by years. Sport-dog and equine practices have used BPC-157, TB-500, oxytocin, and GnRH agonists routinely for tendon, mucosal, reproductive, and behavioral indications. Here is the per-species, per-peptide reality.

🔬 Veterinary peptide therapy is the closest thing to "real-world clinical experience" you can find for compounds that lack human RCTs. Vets see effect or no-effect across hundreds of patients. Anecdotal case-series in dogs and horses provide a useful sanity check on the human optimism — the response patterns are similar enough to be informative.

BPC-157 Daily
(Dogs, Cats)

TB-500 Weekly
Dose (Dogs)

Established Vet
Use Cases

Mechanism of Action

How It Works

🐕

Dogs

Strongest veterinary use case. BPC-157 (5-10 mcg/kg/day) for ACL/CCL recovery, hip dysplasia, IBD. TB-500 (0.1-0.25 mg/kg/wk) for soft-tissue injury and broader recovery. GHK-Cu for chronic wounds and post-surgical healing. Both oral capsules and SubQ injection used.

🐈

Cats

Less established but growing. BPC-157: 5-7 mcg/kg/day for IBD, 3-5 mcg/kg/day for senior arthritis, 5 mcg/kg/day for wound healing. TB-500: 0.5-2.5 mg twice weekly depending on weight. SubQ in scruff, 31G insulin syringe is the standard administration.

🐎

Horses

Equine TB-500 has the longest research history of any veterinary peptide use — back to the early 2000s. IM injection, soft-tissue and tendon repair indications. Oxytocin clinically used for endometritis and placental expulsion. GnRH agonists (deslorelin) for reproductive management.

🦜

Exotic Pets

Birds: oxytocin and vasotocin for egg-binding in budgerigars and cockatiels. Fish/aquaculture: GnRH agonists for breeding stimulation in carp and catfish. Zoo animals: deslorelin and leuprolide for reproductive management of captive populations.

Data

What the Data Shows

Dogs — BPC-157 Tendon/Joint Recovery

Most established veterinary use

Strong

Cats — BPC-157 IBD / Arthritis

Growing case-series, dose-by-weight

Emerging

Horses — TB-500 Soft Tissue

Equine research established 2000s

Established

Cancer / Active Tumor Contraindication

Angiogenic concern across species

Strong

Veterinary RCT Evidence (Any Species)

Controlled trials in pets

Sparse

Bottom Line

Key Takeaways

✅ What We Know

Dogs: BPC-157 most used (ACL/CCL, hip dysplasia, IBD) at 5-10 mcg/kg daily
Cats: BPC-157 5-7 mcg/kg/day for IBD; 3-5 mcg/kg/day for senior arthritis (lower than dog dose)
Horses: TB-500 most established peptide (IM, soft tissue) — 20+ years of veterinary use
TB-500 in dogs: 0.1-0.25 mg/kg weekly with 2-4 week loading then maintenance
Active or high-risk cancer is a contraindication across species (angiogenic concerns)
SubQ in scruff with 31G insulin syringe is standard for cats and small dogs
Refrigerate reconstituted peptides; protect from light
No RCT data exists in any pet species — clinical use is observational

⚠️ What We Don't Know

Long-term safety in pets at chronic-use doses (>3 months continuous)
Dose extrapolation between species (rabbit vs rat vs dog vs human pharmacokinetics differ)
Whether oral capsule formulations have systemic bioavailability in cats
Whether peptide cycles in pets need on/off scheduling like human secretagogue cycling
How USDA / state-level veterinary regulations evolve as compounding shifts

FAQ

Frequently Asked Questions

Are peptides safe for pets?

Veterinary case-series spanning over a decade (BPC-157 in dogs, TB-500 in horses) report no serious adverse events in clinical use. That said, no controlled veterinary RCTs have been conducted, USDA/FDA do not regulate veterinary peptide use, and quality varies widely between vendors. The strongest safety signal is the absence of severe reactions in the empirical record — but absence of evidence is not evidence of absence. Veterinary supervision is essential.

How do I dose peptides for my dog?

BPC-157: 1-2.5 mcg/kg twice daily SubQ, or 5-10 mcg/kg/day total for systemic indications. TB-500: 0.1-0.25 mg/kg weekly with a 2-4 week loading phase. For a 30 kg (66 lb) dog: BPC-157 ~30-75 mcg per dose, TB-500 ~3-7.5 mg per week. Veterinary input on dose selection is strongly recommended for senior animals and those on multiple medications.

How is dosing different for cats?

Lower per-kg dosing than dogs in most published case-series — 3-5 mcg/kg/day for arthritis vs 5-10 mcg/kg/day in dogs. Cats are also more sensitive to compounding excipients; bacteriostatic water is the standard, but verify with your veterinarian. SubQ in the scruff with a 31G insulin syringe is standard administration; many cats tolerate this well.

Can I use the same peptides for horses?

Equine peptide use is the longest-established. TB-500 specifically has a 20+ year veterinary record in horses, primarily IM for soft-tissue injury. BPC-157 is also used. Horse dosing is per-weight scaled — typically 2-5 mg of TB-500 weekly. Consult an equine veterinarian, especially for racehorses where regulatory testing applies.

What pets should NOT receive peptides?

Animals with active or high-risk cancers — angiogenic peptides (BPC-157, TB-500) could theoretically support tumor blood supply. Senior pets with subclinical malignancies are a particular concern; "age-appropriate cancer screening" before starting is advised. Animals on long-term NSAIDs need vet review; the GI-protective effects of BPC-157 may interact unpredictably. Pregnant animals: oxytocin specifically is contraindicated except in obstetric supervision.